Article(id=1329870685322719484, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.05.018, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1671033600000, receivedDateStr=2022-12-15, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995479182, onlineDateStr=2026-11-18, pubDate=1683648000000, pubDateStr=2023-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995479182, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995479182, creator=13701087609, updateTime=1794995479182, updator=13701087609, issue=Issue{id=1329870676980248727, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='5', pageStart='397', pageEnd='520', issueExtLink='null', onlineDate='null', pubDate='1683648000000', pubDateStr='2023-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995477194, creator='13701087609', updateTime=1794995882565, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872377695023554, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872377695023555, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=513, endPage=520, ext={EN=ArticleExt(id=1329870685511463165, articleId=1329870685322719484, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in research on different status of HER2 in breast cancer and its drugs, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Breast cancer is the first malignant tumor, which seriously threatens women's life and health. HER2-targeted therapies have experienced more than 20 years of development and are important biomarkers affecting the prognosis and treatment strategies of breast cancer. Current guidelines use the combined detection method IHC and ISH to detect HER2 expressions, status in breast cancer. There is a consensus that classifying the HER2-low in negative patients. Anti-HER2 drugs on the market include antibodies, small-molecule drugs and ADCs, which can be used for effective treatment of different expression of HER2. This article reviewed the different expression status of HER2 in breast cancer and the research progress of anti-HER2 drugs.

, authors=Menghao ZHAO, Di LI, Guangxin XIA*, authorsList=Menghao ZHAO, Di LI, Guangxin XIA, authorCompany=null, correspAuthors=Guangxin XIA, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329870685805064446, articleId=1329870685322719484, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=HER2在乳腺癌中不同表达状态及治疗药物研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

乳腺癌(breast cancer)是严重威胁女性生命健康的第1大恶性肿瘤。以HER2为靶向的治疗经历20多年的发展,是影响乳腺癌患者预后和治疗策略的重要生物标志物。目前国内外指南推荐使用IHC与ISH相结合的方法检测HER2表达状态,并有共识在阴性患者中区分出HER2低表达。市场上治疗乳腺癌的药物包括抗体药物、小分子药物及ADC,可以针对HER2不同表达状态进行较为有效的治疗。该文针对HER2在乳腺癌中不同表达状态及治疗药物研究进展进行综述。

, authors=赵蒙浩, 李迪, 夏广新*, authorsList=赵蒙浩, 李迪, 夏广新, authorCompany=null, correspAuthors=夏广新, authorNote=

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

, correspAuthorsNote=
夏广新,教授级高级工程师,研究方向:抗肿瘤、自身免疫和精神神经等药物研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Ow4G5OujGe7Rr/gSLJfhXw==, magXml=hXnfqMMfEJwc2ucVQENOLA==, pdfUrl=null, pdf=8jEa64l6adCGSKygw1UZFg==, pdfFileSize=1582175, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=n5Z89ftWqh/zbrQnJVSQ5Q==, mapNumber=null, fund=null)}, authors=[Author(id=1329870686056722691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870686123831557, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686056722691, language=EN, stringName=Menghao ZHAO, firstName=Menghao, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686190940422, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686056722691, language=CN, stringName=赵蒙浩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海医药集团股份有限公司,上海 201203, bio={"content":"

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

"}, bioImg=null, bioContent=

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])]), Author(id=1329870686245466376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870686312575242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686245466376, language=EN, stringName=Di LI, firstName=Di, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686379684107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686245466376, language=CN, stringName=李迪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海医药集团股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])]), Author(id=1329870686450987277, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870686534873359, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686450987277, language=EN, stringName=Guangxin XIA, firstName=Guangxin, middleName=null, lastName=XIA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686597787920, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686450987277, language=CN, stringName=夏广新, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海医药集团股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])])], keywords=[Keyword(id=1329870686698451217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=EN, orderNo=1, keyword=breast cancer), Keyword(id=1329870686807503122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=EN, orderNo=2, keyword=different HER2 expression), Keyword(id=1329870686870417683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=EN, orderNo=3, keyword=drugs), Keyword(id=1329870686929137940, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=CN, orderNo=1, keyword=乳腺癌), Keyword(id=1329870687054967061, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=CN, orderNo=2, keyword=HER2不同表达), Keyword(id=1329870687113687318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, language=CN, orderNo=3, keyword=药物)], refs=[Reference(id=1329870687201767703, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249., articleTitle=null, refAbstract=null), Reference(id=1329870687268876568, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=张雅聪, 吕章艳, 宋方方, 等. 全球及我国乳腺癌发病和死亡变化趋势[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 14-20., articleTitle=null, refAbstract=null), Reference(id=1329870687319208217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志, 2019, 48(3): 169-175., articleTitle=null, refAbstract=null), Reference(id=1329870687386317082, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Tarantino P, Hamilton E, Tolaney S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962., articleTitle=null, refAbstract=null), Reference(id=1329870687457620251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182., articleTitle=null, refAbstract=null), Reference(id=1329870687520534812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Pestalozzi B C, Holmes E, De Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)[J]. Lancet Oncol, 2013, 14(3): 244-248., articleTitle=null, refAbstract=null), Reference(id=1329870687583449373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Nitta H, Kelly B D, Allred C, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future[J]. Pathol Int, 2016, 66(6): 313-324., articleTitle=null, refAbstract=null), Reference(id=1329870687646363934, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Pahuja K B, Nguyen T T, Jaiswal B S, et al. Actionable Activating Oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations[J]. Cancer Cell, 2018, 34(5): 792-806., articleTitle=null, refAbstract=null), Reference(id=1329870687717667103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Prat A, Bardia A, Curigliano G, et al. An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-low)[J]. J Am Med Assoc Oncol, 2022, 8(11): 1676-1687., articleTitle=null, refAbstract=null), Reference(id=1329870687797358880, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20., articleTitle=null, refAbstract=null), Reference(id=1329870687864467745, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Hurvitz S A. DESTINY-changing results for advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 75-76., articleTitle=null, refAbstract=null), Reference(id=1329870687927382306, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Bellati F, Napoletano C, Ruscito I, et al. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy[J]. J Clin Oncol, 2010, 28(21): e369-e371., articleTitle=null, refAbstract=null), Reference(id=1329870687994491171, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Rugo H S, Im S A, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2021, 7(4): 573-584., articleTitle=null, refAbstract=null), Reference(id=1329870688069988644, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Moasser MM. Inactivating amplified HER2: challenges, dilemmas, and future directions[J]. Cancer Res, 2022, 82(16): 2811-2820., articleTitle=null, refAbstract=null), Reference(id=1329870688128708901, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Early Breast Cancer Trialists' Collaborative G. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials[J]. Lancet Oncol, 2021, 22(8): 1139-1150., articleTitle=null, refAbstract=null), Reference(id=1329870688191623463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Sakai K, Yokote H, Murakami-Murofushi K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway[J]. Cancer Sci, 2007, 98(9): 1498-1503., articleTitle=null, refAbstract=null), Reference(id=1329870688258732328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Agus D B, Gordon M S, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer[J]. J Clin Oncol, 2005, 23(11): 2534-2543., articleTitle=null, refAbstract=null), Reference(id=1329870688330035497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Agus D B, Akita R W, Fox W D, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth[J]. Cancer Cell, 2002, 2(2): 127-137., articleTitle=null, refAbstract=null), Reference(id=1329870688384561450, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Nahta R, Hung M C, Esteva F J. The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells[J]. Cancer Res, 2004, 64(7): 2343-2346., articleTitle=null, refAbstract=null), Reference(id=1329870688447476011, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Swain S M, Miles D, Kim S B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530., articleTitle=null, refAbstract=null), Reference(id=1329870688502001964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase Ⅲ, randomized, double-blind, placebo-controlled study[J]. Breast Cancer Res Treat, 2020, 182(3): 689-697., articleTitle=null, refAbstract=null), Reference(id=1329870688573305133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32., articleTitle=null, refAbstract=null), Reference(id=1329870688644608302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for Patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2020, 6(3): e193692., articleTitle=null, refAbstract=null), Reference(id=1329870688715911471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee K-S, Wang X, Im Y H, et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study[J]. J Clin Oncol, 2022, 40(16_suppl): 1031, articleTitle=null, refAbstract=null), Reference(id=1329870688783020336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Ji D, Zhang J, Shen W, et al. Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 1041., articleTitle=null, refAbstract=null), Reference(id=1329870688850129201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang J, Ji D, Cai L, et al. First-in-human HER2-targeted bispecific antibody N026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase Ⅰstudy[J]. Clin Cancer Res, 2022, 28(4): 618-628., articleTitle=null, refAbstract=null), Reference(id=1329870688908849458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南[M]. 北京: 人民卫生出版社, 2022., articleTitle=null, refAbstract=null), Reference(id=1329870688971764019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Chan A, Delaloge S, Holmes F A, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 367-377., articleTitle=null, refAbstract=null), Reference(id=1329870689089204532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Martin M, Holmes F A, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1688-1700., articleTitle=null, refAbstract=null), Reference(id=1329870689160507701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Saura C, Oliveira M, Feng Y H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149., articleTitle=null, refAbstract=null), Reference(id=1329870689223422262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu B, Yan M, Ma F, et al. Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial[J]. J Clin Oncol, 2020, 38(15-suppl): 1003., articleTitle=null, refAbstract=null), Reference(id=1329870689294725431, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Trans Breast Cancer Res, 2020, 1: 13-13., articleTitle=null, refAbstract=null), Reference(id=1329870689353445688, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial[J]. Bio Med Central Med, 2022, 20(1): 498., articleTitle=null, refAbstract=null), Reference(id=1329870689407971641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu B, Yan M, Ma F, et al. LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase Ⅲ trial[J]. Ann Oncol, 2022, 33(suppl-7): S808-S869., articleTitle=null, refAbstract=null), Reference(id=1329870689462497594, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2 CLIMB): final overall survival analysis[J]. Ann Oncol, 2022, 33(3): 321-329., articleTitle=null, refAbstract=null), Reference(id=1329870689512829243, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Li D, Tu Y, Jin K, et al. Discovery of SPH5030, aselective, potent, and irreversible tyrosine kinase inhibitor for HER2-amplified and HER2-mutant cancer treatment[J]. J Med Chem, 2022, 65(7): 5334-5354., articleTitle=null, refAbstract=null), Reference(id=1329870689575743804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Irie H, Ito K, Fujioka Y, et al. TAS0728, A Covalent-binding, HER2-selective kinase inhibitor shows potent antitumor activity in preclinical models[J]. Mol Cancer Ther, 2019, 18(4): 733-742., articleTitle=null, refAbstract=null), Reference(id=1329870689638658365, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Von Minckwitz G, Huang C S, Mano M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628., articleTitle=null, refAbstract=null), Reference(id=1329870689697378622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Laakmann E, Muller V, Schmidt M, et al. Systemic treatment options for HER2-positive breast cancer patients with brain Metastases beyond Trastuzumab: A Literature Review[J]. Breast Care (Basel), 2017, 12(3): 168-171., articleTitle=null, refAbstract=null), Reference(id=1329870689751904575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity[J]. Cancer Sci, 2016, 107(7): 1039-1046., articleTitle=null, refAbstract=null), Reference(id=1329870689810624832, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Andrikopoulou A, Zografos E, Liontos M, et al. Trastuzumab deruxtecan (DS-8201a): The latest research and advances in breast cancer[J]. Clin Breast Cancer, 2021, 21(3): e212-e219., articleTitle=null, refAbstract=null), Reference(id=1329870689869345089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Modi S, Park H, Murthy R K, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896., articleTitle=null, refAbstract=null), Reference(id=1329870689936453954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Bon G, Pizzuti L, Laquintana V, et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study[J]. J Exp Clin Cancer Res, 2020, 39(1): 279., articleTitle=null, refAbstract=null), Reference(id=1329870690011951427, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer[J]. J Natl Cancer Inst, 2007, 99(8): 628-638., articleTitle=null, refAbstract=null), Reference(id=1329870690095837508, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Zuo W J, Jiang Y Z, Wang Y J, et al. Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer[J]. Clin Cancer Res, 2016, 22(19): 4859-4869., articleTitle=null, refAbstract=null), Reference(id=1329870690196500805, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Schwarz L J, Hutchinson K E, Rexer B N, et al. An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression[J]. J Natl Cancer Inst, 2017, 109(11): djx065., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.05.018, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.05.018, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.05.018, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.05.018, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1683648000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
HER2在乳腺癌中不同表达状态及治疗药物研究进展
赵蒙浩 , 李迪 , 夏广新 *
世界临床药物 | 综述评论 2023,44(5): 513-520
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (5) : 513 -520
HER2在乳腺癌中不同表达状态及治疗药物研究进展
全屏
[Author(id=1329870686056722691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870686123831557, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686056722691, language=EN, stringName=Menghao ZHAO, firstName=Menghao, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686190940422, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686056722691, language=CN, stringName=赵蒙浩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海医药集团股份有限公司,上海 201203, bio={"content":"

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

"}, bioImg=null, bioContent=

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])]), Author(id=1329870686245466376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870686312575242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686245466376, language=EN, stringName=Di LI, firstName=Di, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686379684107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686245466376, language=CN, stringName=李迪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海医药集团股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])]), Author(id=1329870686450987277, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870686534873359, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686450987277, language=EN, stringName=Guangxin XIA, firstName=Guangxin, middleName=null, lastName=XIA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870686597787920, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, authorId=1329870686450987277, language=CN, stringName=夏广新, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海医药集团股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870685989613823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, xref=null, ext=[AuthorCompanyExt(id=1329870685993808128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China), AuthorCompanyExt(id=1329870686002196737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870685322719484, companyId=1329870685989613823, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海医药集团股份有限公司,上海 201203)])])]
赵蒙浩, 李迪, 夏广新*
作者信息
  • 上海医药集团股份有限公司,上海 201203
通讯作者:
夏广新,教授级高级工程师,研究方向:抗肿瘤、自身免疫和精神神经等药物研究。
作者简介:

赵蒙浩,药化高级研究员,研究方向:抗肿瘤药物研究。

Advances in research on different status of HER2 in breast cancer and its drugs
Menghao ZHAO, Di LI, Guangxin XIA*
Affiliations
  • Shanghai Pharmaceutical Group Co, LTD Shanghai 201203, China
出版时间: 2023-05-10 doi: 10.13683/j.wph.2023.05.018
文章导航
收藏切换

乳腺癌(breast cancer)是严重威胁女性生命健康的第1大恶性肿瘤。以HER2为靶向的治疗经历20多年的发展,是影响乳腺癌患者预后和治疗策略的重要生物标志物。目前国内外指南推荐使用IHC与ISH相结合的方法检测HER2表达状态,并有共识在阴性患者中区分出HER2低表达。市场上治疗乳腺癌的药物包括抗体药物、小分子药物及ADC,可以针对HER2不同表达状态进行较为有效的治疗。该文针对HER2在乳腺癌中不同表达状态及治疗药物研究进展进行综述。

乳腺癌  /  HER2不同表达  /  药物

Breast cancer is the first malignant tumor, which seriously threatens women's life and health. HER2-targeted therapies have experienced more than 20 years of development and are important biomarkers affecting the prognosis and treatment strategies of breast cancer. Current guidelines use the combined detection method IHC and ISH to detect HER2 expressions, status in breast cancer. There is a consensus that classifying the HER2-low in negative patients. Anti-HER2 drugs on the market include antibodies, small-molecule drugs and ADCs, which can be used for effective treatment of different expression of HER2. This article reviewed the different expression status of HER2 in breast cancer and the research progress of anti-HER2 drugs.

breast cancer  /  different HER2 expression  /  drugs
赵蒙浩, 李迪, 夏广新. HER2在乳腺癌中不同表达状态及治疗药物研究进展. 世界临床药物, 2023 , 44 (5) : 513 -520 . DOI: 10.13683/j.wph.2023.05.018
Menghao ZHAO, Di LI, Guangxin XIA. Advances in research on different status of HER2 in breast cancer and its drugs[J]. World Clinical Drug, 2023 , 44 (5) : 513 -520 . DOI: 10.13683/j.wph.2023.05.018

参考文献 引证文献
排序方式:
[1]
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
张雅聪, 吕章艳, 宋方方, 等. 全球及我国乳腺癌发病和死亡变化趋势[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 14-20.
[3]
编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志, 2019, 48(3): 169-175.
[4]
Tarantino P, Hamilton E, Tolaney S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
[5]
Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182.
[6]
Pestalozzi B C, Holmes E, De Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)[J]. Lancet Oncol, 2013, 14(3): 244-248.
[7]
Nitta H, Kelly B D, Allred C, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future[J]. Pathol Int, 2016, 66(6): 313-324.
[8]
Pahuja K B, Nguyen T T, Jaiswal B S, et al. Actionable Activating Oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations[J]. Cancer Cell, 2018, 34(5): 792-806.
[9]
Prat A, Bardia A, Curigliano G, et al. An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-low)[J]. J Am Med Assoc Oncol, 2022, 8(11): 1676-1687.
[10]
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[11]
Hurvitz S A. DESTINY-changing results for advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 75-76.
[12]
Bellati F, Napoletano C, Ruscito I, et al. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy[J]. J Clin Oncol, 2010, 28(21): e369-e371.
[13]
Rugo H S, Im S A, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2021, 7(4): 573-584.
[14]
Moasser MM. Inactivating amplified HER2: challenges, dilemmas, and future directions[J]. Cancer Res, 2022, 82(16): 2811-2820.
[15]
Early Breast Cancer Trialists' Collaborative G. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials[J]. Lancet Oncol, 2021, 22(8): 1139-1150.
[16]
Sakai K, Yokote H, Murakami-Murofushi K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway[J]. Cancer Sci, 2007, 98(9): 1498-1503.
[17]
Agus D B, Gordon M S, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer[J]. J Clin Oncol, 2005, 23(11): 2534-2543.
[18]
Agus D B, Akita R W, Fox W D, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth[J]. Cancer Cell, 2002, 2(2): 127-137.
[19]
Nahta R, Hung M C, Esteva F J. The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells[J]. Cancer Res, 2004, 64(7): 2343-2346.
[20]
Swain S M, Miles D, Kim S B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530.
[21]
Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase Ⅲ, randomized, double-blind, placebo-controlled study[J]. Breast Cancer Res Treat, 2020, 182(3): 689-697.
[22]
Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32.
[23]
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for Patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2020, 6(3): e193692.
[24]
Lee K-S, Wang X, Im Y H, et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study[J]. J Clin Oncol, 2022, 40(16_suppl): 1031
[25]
Ji D, Zhang J, Shen W, et al. Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 1041.
[26]
Zhang J, Ji D, Cai L, et al. First-in-human HER2-targeted bispecific antibody N026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase Ⅰstudy[J]. Clin Cancer Res, 2022, 28(4): 618-628.
[27]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南[M]. 北京: 人民卫生出版社, 2022.
[28]
Chan A, Delaloge S, Holmes F A, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 367-377.
[29]
Martin M, Holmes F A, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1688-1700.
[30]
Saura C, Oliveira M, Feng Y H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149.
[31]
Xu B, Yan M, Ma F, et al. Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial[J]. J Clin Oncol, 2020, 38(15-suppl): 1003.
[32]
Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Trans Breast Cancer Res, 2020, 1: 13-13.
[33]
Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial[J]. Bio Med Central Med, 2022, 20(1): 498.
[34]
Xu B, Yan M, Ma F, et al. LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase Ⅲ trial[J]. Ann Oncol, 2022, 33(suppl-7): S808-S869.
[35]
Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2 CLIMB): final overall survival analysis[J]. Ann Oncol, 2022, 33(3): 321-329.
[36]
Li D, Tu Y, Jin K, et al. Discovery of SPH5030, aselective, potent, and irreversible tyrosine kinase inhibitor for HER2-amplified and HER2-mutant cancer treatment[J]. J Med Chem, 2022, 65(7): 5334-5354.
[37]
Irie H, Ito K, Fujioka Y, et al. TAS0728, A Covalent-binding, HER2-selective kinase inhibitor shows potent antitumor activity in preclinical models[J]. Mol Cancer Ther, 2019, 18(4): 733-742.
[38]
Von Minckwitz G, Huang C S, Mano M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
[39]
Laakmann E, Muller V, Schmidt M, et al. Systemic treatment options for HER2-positive breast cancer patients with brain Metastases beyond Trastuzumab: A Literature Review[J]. Breast Care (Basel), 2017, 12(3): 168-171.
[40]
Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity[J]. Cancer Sci, 2016, 107(7): 1039-1046.
[41]
Andrikopoulou A, Zografos E, Liontos M, et al. Trastuzumab deruxtecan (DS-8201a): The latest research and advances in breast cancer[J]. Clin Breast Cancer, 2021, 21(3): e212-e219.
[42]
Modi S, Park H, Murthy R K, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896.
[43]
Bon G, Pizzuti L, Laquintana V, et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study[J]. J Exp Clin Cancer Res, 2020, 39(1): 279.
[44]
Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer[J]. J Natl Cancer Inst, 2007, 99(8): 628-638.
[45]
Zuo W J, Jiang Y Z, Wang Y J, et al. Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer[J]. Clin Cancer Res, 2016, 22(19): 4859-4869.
[46]
Schwarz L J, Hutchinson K E, Rexer B N, et al. An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression[J]. J Natl Cancer Inst, 2017, 109(11): djx065.
2023年第44卷第5期
17
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.05.018
  • 接收时间:2022-12-15
  • 首发时间:2026-11-18
  • 出版时间:2023-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-12-15
基金
作者信息
    上海医药集团股份有限公司,上海 201203

通讯作者:

夏广新,教授级高级工程师,研究方向:抗肿瘤、自身免疫和精神神经等药物研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.05.018
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏